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Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disease that belongs to the group of spondyloarthritis,
which involves the spine, peripheral joints and entheses.
Juvenile-onset AS affects children under the age of 16
years and present a clinical course different from adult-
onset AS. Several randomized clinical trials have shown
that TNF antagonists are an effective alternative treat-
ment in adult-onset AS. Similar results have been
reported in juvenile-onset AS, but have been fewer stu-
dies conducted in this group of patients.
Objectives
To compare the safety and retention rate of TNF
antagonist therapy in patients with juvenile-onset and
adult-onset AS.
Methods
Analysis of patients with adult-onset and juvenile-onset
AS included in the Spanish registry BIOBADASER 2.0
(October 2006 to November 2012). Incidence rates (irs)
of adverse events (aes) and rates of discontinuation were
compared between both groups.
Results
A total of 686 patients (524 males, 162 females) were
included, comprising 33 juvenile-onset AS and 653
adult-onset AS patients. The ages of diagnosis were 11.9
± 0.7 years and 34.4 ± 0.5 for juvenile-onset and adult-
onset AS, respectively. The duration of disease was
higher in the juvenile-onset group (17.9 ± 1.9 years)
than in the adult-onset group (9.3 ± 0.4) and HLA-B27
positivity was similar in both groups (82.4% and 86.4%,
respectively). Axial involvement was higher in adult-
onset patients (74.9% vs 63.6%) and peripheral involve-
ment was more common in juvenile-onset AS (45.5% vs
32.5%). The TNF antagonist more frequently used as
first treatment was infliximab in both adult-onset
(48.5%) and juvenile-onset AS (50%), and sulfasalazine
or other DMARD were used concomitantly in 43% and
35.5%, respectively. The irs of aes was largest in adult-
onset AS (140.5 events/1000 patient-years, CI 95%: 13.2-
15.8) and lowest in juvenile-onset AS (30 events/1000
patient-years, CI 95%: 0.0-1.9), but severe adverse events
were similar in both groups (43 events/1000 patient-
years, in adult-onset AS [CI 95%: 3.7-5.1], and 44
events/1000 patient-years in juvenile-onset AS [CI 95%:
2.3-7.5]). The rates of discontinuation due to aes and
inefficacy were both higher in adult-onset AS (3,7 [CI
95%: 3.1-4.3] and 2,1 [CI 95%: 1.7-2.6], respectively)
compared with juvenile-onset AS (2,7 [CI 95%:1,2-5,3]
and 1,3 [CI 95%:0,4-3,4], respectively).
Conclusion
The safety and retention patterns of TNF antagonist
therapy were similar in adult-onset and juvenile-onset1Rheumatology, University Hospital Ramon y Cajal, Madrid, Spain
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